Trial reportBiological psychiatry2013
Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.
Trial report in Biological psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Interventions for preventing weight gain after smoking cessation.The Cochrane database of systematic reviews · 2021Pooled it
- Opioid antagonists for smoking cessation.The Cochrane database of systematic reviews · 2013Pooled it
- Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase.Psychoneuroendocrinology · 2015Trial
- Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.The American journal of drug and alcohol abuse · 2015Trial
- A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.Journal of clinical psychopharmacology · 2014Trial
- Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.Psychopharmacology · 2014Trial
- Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.Addiction (Abingdon, England) · 2013Trial
- Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system.Drug and alcohol dependence · 2021Article
- Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial.Alcohol and alcoholism (Oxford, Oxfordshire) · 2019Article
- Sex and gender differences in substance use disorders.Clinical psychology review · 2018Review
- Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia.Frontiers in pharmacology · 2018Article
- Endogenous opioid system: a promising target for future smoking cessation medications.Psychopharmacology · 2017Review
- The effectiveness of naltrexone combined with current smoking cessation medication to attenuate post smoking cessation weight gain: a literature review.Journal of pharmaceutical policy and practice · 2017Review
- Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers.Current addiction reports · 2016Article
- Gender Considerations in Addiction: Implications for Treatment.Current treatment options in psychiatry · 2015Article
- The overlap between binge eating disorder and substance use disorders: Diagnosis and neurobiology.Journal of behavioral addictions · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe opioid antagonist naltrexone has shown promise to reduce weight gain during active treatment, but longer-term studies have not been conducted. The goal was to examine effects of naltrexone on weight gain over long-term follow-up in men and women who quit smoking.
methodsWeight was examined at baseline and 6- and 12-month follow-up in the two largest randomized, double-blind, placebo-controlled trials of naltrexone in nicotine dependence. For 6-12 weeks after the quit date, participants were randomly assigned to receive naltrexone or placebo. Behavioral counseling and open-label nicotine patch were also included for the first 4-6 weeks. Of the 700 participants in the combined intent-to-treat sample, there were 159 (77 women) biochemically verified abstinent smokers at 6 months, and 115 (57 women) of them remained abstinent at 12 months. Changes in weight (in kilograms or in percentage) and body mass index from baseline to the follow-ups were assessed for these participants.
resultsWeight gain was significantly lower for women treated with naltrexone compared with placebo (6 months, 3.3 vs. 5.5 kg; 12 months, 5.9 vs. 7.4 kg, respectively). Increases in body mass index and percentage body weight gain were also significantly lower in women treated with naltrexone versus placebo. These effects were not observed in men.
conclusionThe results provide evidence for naltrexone as the first pharmacotherapy to reduce postsmoking cessation weight gain among women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.